Pharmacy Medical News about Mycophenolate

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Mycophenolate mofetil: An update
Drugs of Today, 11/05/09

Villarroel MC et al. – Mycophenolic acid (MPA) is a potent, selective, noncompetitive and reversible inhibitor of inosine–5'–monophosphate deshydrogenase (IMPDH). By depleting guanosine and deoxyguanosine nucleotides in T and B lymphocytes it inhibits their proliferation and, hence, immunoglobin (Ig) production. MPA also suppresses dendritic cell maturation decreasing its capacity of antigen presentation to T lymphocytes.

<< Previous
Bazedoxifene acetate: A novel selective estrogen receptor...

Next >>
The vacuole-targeting fungicidal activity of amphotericin B...

A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis
Rheumatology, 10/23/09 Relevance Score: 85%

A prospective randomized open study in liver transplant recipients: Daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids
Liver Transplantation, 11/03/09 Relevance Score: 84%

Severe acute fibrinous and organizing pneumonia (AFOP) causing ventilatory failure: Successful treatment with mycophenolate mofetil and corticosteroids
Respiratory Medicine, 10/14/09 Relevance Score: 84%

Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis
Kidney International, 11/05/09 Relevance Score: 83%

Safety and Tolerance of Sodium Mycophenolate in Patients After Renal Transplantation--An Observational Study
Transplantation Proceedings, 11/05/09 Relevance Score: 83%